18th, 19th & 20th
Deira Creek, Dubai
Raytheon Healthcare is pleased to invites participants from all over the world to attend "The International Conference on Genomics and Personalized Medicine - 2018" during April 18th -20th, 2018 at Dubai, which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.
Genomics and other omics technologies are playing an increasingly important role in health care, and new sensors are being developed to help manage personal health. Spurred by the revolution in DNA sequencing technologies, it is now possible to sequence the genome of patients with cancer, undiagnosed disease and even healthy individuals to help tailor treatment for a specific individual’s disease. This entire area is moving extremely rapidly in terms of technology, data, its management and analysis, and clinical uptake. The goal of this meeting is to bring together leaders in technology development, basic scientists, engineers and clinicians to advance human health. It intends to: 1) Help researchers and clinicians keep abreast of the latest developments; 2) Stimulate collaborations; and 3) Spur the development of new technologies that will improve personalized medicine.
The International Conference on Genomics and Personalized Medicine - 2018 will brings together a host of senior level experts to discuss recent developments in the industry and debate the best strategies and solutions to improve Personal Health. The conference will host more than 50 world-class speakers from academia and industry who will discuss recent advances in personal Care and innovation going forward. This conference will highlight the latest scientific breakthroughs, explore innovative technologies and approaches that can be used to overcome the recent barriers in treating the critical cases, and bring together industry leaders who will discuss on future opportunities.
At the 2018 congress Specific goals of the meeting include: 1) Providing an overview of computational tools, any gaps in variant detection capabilities and their challenges for clinical implementation; 2) Discussing specific approaches to identify gene-therapy combinations, specifically addressing the difficulty of assessing the impact of DNA mutations on protein function; 3) Identification of the significant efforts ongoing in blood-based ("liquid") biopsy of patients on therapy or following resection surgery; 4) Presentation of current efforts to utilize genomics of individual tumors to inform immunotherapy development; 5) Discussion of efforts at data integration, across "omic" platforms, and also the integration of genomic data with more conventional pathology-based evidence/data.
The scientific program will feature live workshops, interactive education sessions, B2B meetings, round-table discussions apart from the conventional plenary sessions, featured symposia, break out sessions and oral presentation sessions for abstracts and challenging cases.In addition, The International Conference on Genomics and Personalized Medicine - 2018 will feature live cases and interventional courses in an interactive format throughout the conference. Our endeavor is to provide a stimulating and thought- provoking scientific program. We sincerely hope that the blend of pleasant weather, warm hospitality and revitalizing social evenings will make the scientific environment richer.
We look forward to welcoming the participants to this exciting conference which will bring together world leaders in their respective fields in the fascinating and intellectual environment of Dubai
With Warm Regards
P. J. Narayan
Chief Executive Officer
Chief Executive Officer
WHO SHOULD ATTEND
BENEFITS OF ATTENDING
Gain a basic overview of genomic medicine and the future of personalized medicine.
Uncover new findings, best practices and challenges facing the implementation of genomic medicine.
Physicians will learn how to formulate a strategy for genomic testing, interpret genomic test results and implement best practices in the delivery of genomic test results to patients and families.
Individuals with a rare undiagnosed disease, their families and adult adoptees with no family health history have the opportunity to be sequenced and learn from their own genome about their individual potential health risks and drug interactions.